NCT03685578

CERENOVUS Neurothrombectomy Devices Registry

Embotrap eXtraction & Clot EvaLuation & Lesion Evaluation for NeuroThrombectomy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,000 (actual)
• Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A post-market registry evaluating the EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC™ Aspiration Catheter, and CEREGLIDE 71 Intermediate Catheter in acute ischemic stroke patients with confirmed intracranial vessel occlusion.

Detailed description

The objective of this study are to separately assess the effectiveness of the CERENOVUS neurothrombectomy devices (EmboTrap® Revascularization Device, Large Bore Catheter/EMBOVAC Aspiration Catheter, and CEREGLIDE 71 Intermediate Catheter) in a real-world setting, as well as to explore correlations between patient comorbidities, clot characteristics, revascularization rates, and clinical outcomes.

Conditions

• Cerebral Stroke

Interventions

Type	Name	Description
DEVICE	EmboTrap® Revascularization Device	EmboTrap® Revascularization Device
DEVICE	CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter	CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
DEVICE	CEREGLIDE 71 Intermediate Catheter	CEREGLIDE 71 Intermediate Catheter

Timeline

• Start date: 2018-09-28
• Primary completion: 2025-02-20
• Completion: 2025-02-20
• First posted: 2018-09-26
• Last updated: 2025-06-03

Locations

40 sites across 7 countries: United States, Belgium, France, Germany, Israel, Switzerland, United Kingdom

Regulatory

• FDA-regulated device study